Bmi1 Peptide
€100.00
In stock
SKU
350547
Protein Family: Transcription Factors, Ubiquitins
Pathway and Disease: Cancers, Folding, Sorting and Degradation, Transcription
Alternate Names: Polycomb complex protein BMI-1; Polycomb group RING finger protein 4; RING finger protein 51; BMI1; PCGF4; RNF51
Accession No.: P35226, NP_005171
Description:
Polycomb complex protein BMI-1 is a component of the Polycomb group (PcG) multiprotein PRC1 complex that maintains the transcriptionally repressive state of many genes, including Hox genes throughout development. PcG PRC1 complex forms Polycomb bodies that act via chromatin remodeling and histone modification. BMI-1 cooperates with Myc oncogene to produce B-lymphomas.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1962.1 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200185 is selected from a sequence within the C-term region of human Bmi1. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C79H128N30O27S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cancers, Folding, Sorting and Degradation, Transcription
Alternate Names: Polycomb complex protein BMI-1; Polycomb group RING finger protein 4; RING finger protein 51; BMI1; PCGF4; RNF51
Accession No.: P35226, NP_005171
Description:
Polycomb complex protein BMI-1 is a component of the Polycomb group (PcG) multiprotein PRC1 complex that maintains the transcriptionally repressive state of many genes, including Hox genes throughout development. PcG PRC1 complex forms Polycomb bodies that act via chromatin remodeling and histone modification. BMI-1 cooperates with Myc oncogene to produce B-lymphomas.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1962.1 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200185 is selected from a sequence within the C-term region of human Bmi1. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C79H128N30O27S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review